Stem Cell Research and News: Rhode Island
<-- Back To RegionsMultiCell Technologies Appoints Anthony Altig to Board
Experienced Biotechnology Executive to Help Company Develop Therapeutic Platform LINCOLN, RI – September 19, 2005 – Multicell Technologies, Inc. (OTCBB:MCET), a leading adult stem cell company and supplier of immortalized non-tumorigenic human hepatocytes for drug discovery, announced today that it...
Posted in Today's Stem Cell Research on September 23, 2005 11:36 AM
MultiCell Technologies Awarded Pilot Grant for Study of Type 1 Diabetes Therapeutic
LINCOLN, R.I. – September 14, 2005 – MultiCell Technologies, Inc. (OTCBB: MCET), a leading adult stem cell company and a supplier of immortalized non-tumorigenic human hepatocytes for drug discovery applications, announced today that it has been awarded a pilot grant...
Posted in Today's Stem Cell Research on September 22, 2005 05:42 PM
MultiCell Forms New Company to Develop Novel Therapies for Diabetes and Other Autoimmune Diseases
LINCOLN, R.I. – Sept. 7, 2005 – MultiCell Technologies, Inc. (OTCBB: MCET), a leading adult stem cell company and a supplier of immortalized non-tumorigenic human hepatocytes for drug discovery applications, announced that it has formed a new company, MultiCell Immunotherapeutics,...
Posted in Today's Stem Cell Research on September 22, 2005 05:35 PM
Multicell Held Grand Opening At Rhode Island Facilities; Governor Carcieri Was Featured Speaker
LINCOLN, RI September 16, 2005 – Multicell Technologies, (NASDAQ:MCET.OB), whose scientists are known for two key discoveries heretofore not accomplished by other scientists: two patents on ADULT human liver stem cells and functional immortalized non-tumorigenic liver cells, held a grand...
Posted in Today's Stem Cell Research on September 14, 2005 06:12 PM
StemCells Inc. Announces Second Quarter 2005 Financial Results
PALO ALTO, Calif.--(BUSINESS WIRE)--July 29, 2005--StemCells, Inc. (NASDAQ: STEM) today reported its financial results for the second quarter ended June 30, 2005. The Company reported a net loss of $3,868,000, or $0.06 per share, for the second quarter ended June...
Posted in Today's Stem Cell Research on July 29, 2005 03:01 PM
MultiCell Reports Second Quarter 2005 Results
WARWICK, R.I. – (BUSINESS WIRE) – July 18, 2005 – MultiCell Technologies, Inc. (OTCBB: MCET), an innovator in liver cells, announced financial results for its fiscal 2005 second quarter ended May 31, 2005. The Company had revenue of $39,693 versus...
Posted in Today's Stem Cell Research on July 26, 2005 12:02 AM
MultiCell Technologies and XenoTech LLC Jointly Announce Shrink Wrap Vial Sales Launch for Immortalized Hepatocytes
New Procedure Expected to Speed Adoption Through Reduced Sales Cycle LINCOLN, R.I. – (BUSINESS WIRE) – June 15, 2005 – MultiCell Technologies, Inc. (OTCBB: MCET), a leading supplier of immortalized non-tumorgenic human hepatocytes as pharmaceutical candidate optimization tools, announced sales...
Posted in Today's Stem Cell Research on June 16, 2005 11:58 PM
MultiCell Technologies Commences Sales of Immortalized Porcine Hepatocytes
LINCOLN, R.I. – (BUSINESS WIRE) – June 10, 2005 – MultiCell Technologies, Inc. (OTCBB: MCET) a leading supplier of immortalized human hepatic cell lines for pharmaceutical candidate optimization, announced today that it has commenced sales of HepLiu immortalized porcine (pig)...
Posted in Today's Stem Cell Research on June 11, 2005 11:55 PM
MultiCell and XenoTech to Exhibit Immortalized Hepatocytes at New European Exhibition
LINCOLN, R.I.--(BUSINESS WIRE)--Jun 9, 2005 - MultiCell Technologies, Inc. (OTCBB: MCET) a leading supplier of immortalized human hepatic cell lines for pharmaceutical candidate optimization, announced today that it will attend the inaugural Pharmaceutical Sciences Fair and Exhibition in Nice, France,...
Posted in Today's Stem Cell Research on June 9, 2005 08:43 PM
StemCells, Inc. to Present at Morgan Stanley Small Cap Executive Conference
PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 9, 2005 - StemCells, Inc. (NASDAQ: STEM) today announced that it will present at the Morgan Stanley Small Cap Executive Conference in New York, New York on Wednesday, June 15, 2005 at 8:00 am EDT. Following...
Posted in Today's Stem Cell Research on June 9, 2005 08:33 PM
MultiCell Licensee XenoTech Holds Drug Metabolism Symposium
LINCOLN, R.I., June 6, 2005 – MultiCell Technologies, Inc. (OTCBB: MUCL) a leading supplier of immortalized hepatocytes as pharmaceutical candidate optimization tools, announced today that its licensee, XenoTech, LLC, will present MultiCell's unique, functional hepatocytes at a two-day symposium June...
Posted in Today's Stem Cell Research on June 7, 2005 11:51 PM
MultiCell Technologies Announces New Employment Agreement With Dr. Ronald Faris, Ph.D.
LINCOLN, R.I.-- May 31, 2005--MultiCell Technologies, Inc. (OTCBB: MCET), a leading supplier of immortalized non-tumorigenic human hepatocytes as pharmaceutical candidate optimization tools, announced that Ronald Faris, Ph.D., Senior Vice President and Chief Science Officer of the Company, has signed a...
Posted in Today's Stem Cell Research on June 3, 2005 05:04 PM
MultiCell Announces Results of Shareholders' Meeting
LINCOLN, R.I. – (BUSINESS WIRE) – May 19, 2005 – MultiCell Technologies, Inc. (OTCBB: MUCL - NEWS), a leading supplier of immortalized non-tumorigenic human hepatocytes as pharmaceutical candidate optimization tools, announced today the results from its Annual Shareholders meeting held...
Posted in Today's Stem Cell Research on May 23, 2005 06:17 PM
StemCells Announces First Quarter 2005 Financial Results
StemCells, Inc. (NASDAQ: STEM) today reported its financial results for the first quarter ended March 31, 2005. The Company reported a net loss of $3,449,000, or $0.06 per share, for the first quarter ended March 31, 2005, compared to a...
Posted in Today's Stem Cell Research on May 3, 2005 05:15 PM
MultiCell Moves to Larger Facilities to Support Expanding Research Programs
(BUSINESS WIRE) - April 13, 2005 -MultiCell Technologies (OTCBB:MUCL) announced today that it will relocate its offices and laboratory into larger, more modern facilities on April 15th. The new space will significantly upgrade the Company's research capabilities and bring research...
Posted in Today's Stem Cell Research on April 15, 2005 08:06 PM
StemCells, Inc Fourth Quarter and Year End Financials
StemCells, Inc. (NASDAQ: STEM) today reported its financial results for the fourth quarter and the year ended December 31, 2004. The Company reported a loss of $4,919,000, or $0.08 per share, for the fourth quarter ended December 31, 2004, compared...
Posted in Today's Stem Cell Research on March 4, 2005 06:33 PM